Food poisoning is usually caused by food or water contaminated with bacteria, such as E. coli or Salmonella, or viruses like norovirus, rotavirus, and adenovirus, which can cause viral gastroenteritis. According to the Mayo Clinic, viral gastroenteritis is often called “stomach flu” and affects the intestines, causing symptoms such as watery diarrhea, nausea, vomiting, stomach cramps, a low-grade fever, and occasionally muscle aches or headaches.
Although uncomfortable, symptoms of viral gastroenteritis typically last only a few days. However, with the large number of annual global cases, there is a tremendous business opportunity to help ease the suffering with new technologies and treatments. According to a new report by The Business Research Company, the viral gastroenteritis market is projected to be worth $8.1 billion by 2028. Here are some of the highlights:
The viral gastroenteritis market is experiencing significant growth, with projections indicating an increase from $6.34 billion in 2023 to $6.7 billion in 2024. This expansion is driven by several factors, including the rise of viral infections, changes in global hygiene practices, advancements in diagnostic technologies, increased global travel and tourism, and evolving climate and environmental conditions.
A key driver of this market growth is the increasing incidence of gastrointestinal disorders worldwide, which affect the digestive tract. An October 2021 survey highlighted the high global prevalence of functional gastrointestinal disorders, emphasizing the urgent need for more effective treatments and diagnostic tools.
Major pharmaceutical companies like Abbvie Inc., Bayer AG, Pfizer Inc., and Sanofi S.A. are at the forefront of innovation in this market, focused on developing new products, particularly in the area of diagnostics. Last year, Jiangsu Bioperfectus Technologies Co. Ltd. introduced Real-Time PCR (polymerase chain reaction) Kits for “accurate detection of gastrointestinal pathogens, enhancing diagnostic capabilities in clinical settings.”
Several trends are shaping the future of the viral gastroenteritis market. These include advancements in vaccine development, the adoption of telemedicine and other advanced diagnostic techniques, collaborative research initiatives, personalized medicine approaches, and the integration of digital health solutions. The goal is improving patient outcomes and enhancing disease management strategies.
The market is segmented based on various factors including drugs (antibiotics, antacids, laxatives, antimotility agents), diagnosis methods (physical examination, rapid stool test), indications (watery diarrhea, abdominal cramps, pain), types of viruses (norovirus, rotavirus, astrovirus, enteric adenovirus), and end users (hospitals, clinics, pharmaceutical companies, diagnostic centers, ambulatory care centers).
Geographically, while North America dominated the market in 2023, Asia-Pacific is expected to experience the fastest growth during the forecast period. This regional shift highlights the changing dynamics of the global healthcare landscape and presents new opportunities for market players.
Commenting on this story, one national food safety attorney said, “As the viral gastroenteritis market continues to evolve, it presents both challenges and opportunities for healthcare providers, pharmaceutical companies, and patients alike.”
The ongoing focus on innovation, coupled with increasing awareness and improved healthcare infrastructure, is likely to drive further growth and advancements in the treatment and management of viral gastroenteritis.
